Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Preeclampsia Drugs Market Grown from 2024 to 2025?

The market for preeclampsia drugs has seen a swift expansion in the past few years. It’s projected to augment from $1.25 billion in 2024 to $1.38 billion in 2025, with a compound annual growth rate (CAGR) of 10.6%. The growth witnessed in the historic period is due to heightened awareness about maternal health, advancements in research and development, concerns surrounding neonatal health, and early detection methods.

What Growth Rate Is Anticipated for the Preeclampsia Drugs Market in the Coming Years?

Anticipated to experience swift expansion in the upcoming years, the preeclampsia drugs market is projected to reach a value of $2.12 billion by 2029, with a compound annual growth rate (CAGR) of 11.3%. This growth over the forecast period is motivated by aspects such as personalized medicine, non-invasive diagnostic instruments, targeted therapies, and health equity programs. Trends to watch for in this period encompass preventative measures, patient-focused care, consistent monitoring, and regulatory emphasis.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp

Who Are the Leading Companies in the Preeclampsia Drugs Market?

Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.

What Are the Key Drivers of the Preeclampsia Drugs Market?

The surge in diabetes instances among expecting mothers is envisaged to stimulate the progression of the preeclampsia drug market. Diabetes is a long-term metabolic ailment marked by heightened levels of blood glucose or blood sugar. Preeclampsia is an adverse condition during pregnancy marked by increased blood pressure and damage to organs. Metformin, a preeclampsia drug, is commonly administered to pregnant women suffering from premature preeclampsia. In the context of the National Library of Medicine’s report for December 2022, the U.S-based biomedical library and informatics center noted an increase of 6.56% in gestational diabetes mellitus (GDM) incidents, totaling 20,865 cases. This upsurge in diabetes occurrences among pregnant women is expected to fuel the preeclampsia drug market. The escalating incidence of lifestyle diseases or non-communicable diseases (NCDs) is anticipated to drive the growth of the preeclampsia drugs market. NCDs are primarily caused by unhealthy lifestyle habits and behaviors. Preeclampsia drugs are employed to mitigate lifestyle diseases like hypertension, obesity, and diabetes, which contribute to the risk of preeclampsia. The World Health Organization, a Switzerland-based UN affiliate, reported in September 2022 that among the 41 million NCD-related mortalities, 74% were due to chronic illness globally. This figure included 17.9 million deaths from cardiovascular diseases, 9.3 million cancer-related deaths, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Thus, the steadily rising prevalence of lifestyle diseases augments the expansion of the preeclampsia drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13025&type=smp

What Are the Key Market Segments in the Preeclampsia Drugs Industry?

The preeclampsia drugs market covered in this report is segmented –

1) By Type: Mild Preeclampsia, Severe Preeclampsia

2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication

3) By Route of Administration: Oral, Parenteral, Other Route of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Mild Preeclampsia: Blood Pressure Management, Proteinuria Monitoring, Lifestyle Modifications

2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy, Emergency Delivery Management

What Are the Latest Trends in the Preeclampsia Drugs Market?

Prime corporations in the preeclampsia medicine industry are concentrating on the creation of advanced drug solutions in order to strengthen their market standing. In March 2023, for example, Comanche Biopharma Corp., a U.S. biopharmaceutical entity, announced FDA approval of a new investigational drug, CBP-4888, their proprietary siRNA treatment for preeclampsia. CBP-4888 is an siRNA therapy administered subcutaneously, designed to diminish the formation of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The primary source of preeclampsia is the placenta’s excessive generation of protein sFLT1, which then enters the mother’s bloodstream. CBP-4888 has the potential to reduce preeclampsia symptoms like high blood pressure and organ injury, potentially enabling the safer prolongation of pregnancy.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

What Are the Key Regional Markets in the Preeclampsia Drugs Industry?

North America was the largest region in the preeclampsia drugs market in 2024. The regions covered in preeclampsia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13025

This Report Delivers Insight On:

1. How big is the preeclampsia drugs market, and how is it changing globally?

2. Who are the major companies in the preeclampsia drugs market, and how are they performing?

3. What are the key opportunities and risks in the preeclampsia drugs market right now?

4. Which products or customer segments are growing the most in the preeclampsia drugs market?

5. What factors are helping or slowing down the growth of the preeclampsia drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model